ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Feb 17, 2021||ENDRA Life Sciences Announces New Clinical Study Partnership with Inselspital University Hospital in Bern, Switzerland|
|Jan 26, 2021||ENDRA Life Sciences Further Strengthens TAEUS(R) System Intellectual Property Protection with Issuance of 14th U.S. Patent|
|Jan 13, 2021||ENDRA Life Sciences Granted 13th U.S. Patent for its TAEUS(R) Platform Technology|
|Jan 08, 2021||ENDRA Life Sciences to Present at H.C. Wainwright Virtual BioConnect 2021 Conference|
|Dec 23, 2020||ENDRA Life Sciences Issued Chinese Patent for Its TAEUS(R) Platform Technology to Calculate Fat Concentration in Tissue|
|Day Range||2.46 - 2.69|
|52 Week Range||0.60 - 2.99|
|Bid/Ask||2.61 / 2.62|
|Bid/Ask Size||1,300 X 2,700|
|Market Cap||88.81 million|
|Shares Outstanding||33.64 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|